Literature DB >> 18177595

T cells in psoriatic arthritis.

Ernest Choy1.   

Abstract

Psoriatic arthritis is characterized by chronic inflammation of the skin and synovial joint. T cells are abundant in the inflamed joint and skin. Disease susceptibility is associated with major histocompatibility complex, which presents antigens to T cells. T cells in the synovial joints have an activated phenotype and demonstrate selective T-cell receptor usage suggestive of oligoclonal expansions. Taken together, these facts suggest that psoriatic arthritis is driven by antigen or autoantigen-driven T-cell activation. The therapeutic benefit of anti-T-cell agents further supports an important pathogenic role for T cells in persistent synovial inflammation and joint damage in psoriatic arthritis.

Entities:  

Mesh:

Year:  2007        PMID: 18177595     DOI: 10.1007/s11926-007-0071-5

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  36 in total

Review 1.  Immunobiologics in the treatment of psoriasis.

Authors:  Benjamin F Chong; Henry K Wong
Journal:  Clin Immunol       Date:  2007-02-21       Impact factor: 3.969

Review 2.  Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands.

Authors:  M C Horowitz; Y Xi; K Wilson; M A Kacena
Journal:  Cytokine Growth Factor Rev       Date:  2001-03       Impact factor: 7.638

3.  Psoriatic arthritis.

Authors:  V Wright; J M Moll
Journal:  Bull Rheum Dis       Date:  1971-01

4.  A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.

Authors:  Gerald G Krueger; Kim A Papp; Dow B Stough; Keith H Loven; Wayne P Gulliver; Charles N Ellis
Journal:  J Am Acad Dermatol       Date:  2002-12       Impact factor: 11.527

5.  Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.

Authors:  A Y Goedkoop; M C Kraan; M B M Teunissen; D I Picavet; M A de Rie; J D Bos; P P Tak
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

6.  Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens.

Authors:  Shane A Curran; Oliver M FitzGerald; Patrick J Costello; Jeanette M Selby; David J Kane; Barry Bresnihan; Robert Winchester
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

Review 7.  T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action.

Authors:  D Jullien; J C Prinz; R G B Langley; I Caro; W Dummer; A Joshi; R Dedrick; P Natta
Journal:  Dermatology       Date:  2004       Impact factor: 5.366

8.  Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis.

Authors:  Jean-Paul Ortonne; Mark Lebwohl; Christopher Em Griffiths
Journal:  Eur J Dermatol       Date:  2003 Mar-Apr       Impact factor: 3.328

9.  Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis.

Authors:  Christopher T Ritchlin; Sally A Haas-Smith; Ping Li; David G Hicks; Edward M Schwarz
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

10.  Predictors for radiological damage in psoriatic arthritis: results from a single centre.

Authors:  Simon J Bond; Vernon T Farewell; Catherine T Schentag; Dafna D Gladman
Journal:  Ann Rheum Dis       Date:  2006-08-17       Impact factor: 19.103

View more
  8 in total

1.  Analysis of Programmed Death-1 in Patients with Psoriatic Arthritis.

Authors:  Michael Peled; Marianne Strazza; Inbar Azoulay-Alfaguter; Gregg J Silverman; Jose U Scher; Adam Mor
Journal:  Inflammation       Date:  2015-08       Impact factor: 4.092

Review 2.  Differentiating Psoriatic Arthritis from Osteoarthritis and Rheumatoid Arthritis: A Narrative Review and Guide for Advanced Practice Providers.

Authors:  William Saalfeld; Amanda M Mixon; Jonna Zelie; Eileen J Lydon
Journal:  Rheumatol Ther       Date:  2021-09-14

Review 3.  The microbiome and psoriatic arthritis.

Authors:  Hester Eppinga; Sergey R Konstantinov; Maikel P Peppelenbosch; H Bing Thio
Journal:  Curr Rheumatol Rep       Date:  2014-03       Impact factor: 4.592

Review 4.  Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy.

Authors:  Arno W R van Kuijk; Paul P Tak
Journal:  Curr Rheumatol Rep       Date:  2011-08       Impact factor: 4.592

Review 5.  New pharmacological strategies in rheumatic diseases.

Authors:  R E Schiotis; A D Buzoianu; D F Mureșanu; S Suciu
Journal:  J Med Life       Date:  2016 Jul-Sep

6.  A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue.

Authors:  A W R van Kuijk; D M Gerlag; K Vos; G Wolbink; M de Groot; M A de Rie; A H Zwinderman; B A C Dijkmans; P P Tak
Journal:  Ann Rheum Dis       Date:  2008-07-22       Impact factor: 19.103

7.  Management of Psoriatic Arthritis: Turkish League Against Rheumatism (TLAR) Expert Opinions.

Authors:  Kemal Nas; Erkan Kiliç; Remzi Çevik; Hatice Bodur; Şebnem Ataman; Figen Ayhan; Özgür Akgül; Ayşen Akinci; Zuhal Altay; Erhan Çapkın; Abdullah Zübeyir Dağli; Tuncay Duruöz; Gülcan Gürer; Feride Göğüş; Yeşim Garip; Cahit Kaçar; Ayhan Kamanli; Ece Kaptanoğlu; Taciser Kaya; Hilal Kocabaş; Erhan Ali Özdemirel; Sumru Özel; İlhan Sezer; İsmihan Sunar; Gürkan Yilmaz
Journal:  Arch Rheumatol       Date:  2018-05-21       Impact factor: 1.472

8.  Abatacept in psoriatic arthritis: Case report and short review.

Authors:  Francesco Ursini; Saverio Naty; Emilio Russo; Rosa Daniela Grembiale
Journal:  J Pharmacol Pharmacother       Date:  2013-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.